Cargando…
Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia
Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP) are common conditions and constitute a substantial socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum of antibacterial activity. In vi...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661642/ https://www.ncbi.nlm.nih.gov/pubmed/18360582 |
_version_ | 1782131056513646592 |
---|---|
author | Zhanel, George G Hisanaga, Tamiko Wierzbowski, Aleksandra Hoban, Daryl J |
author_facet | Zhanel, George G Hisanaga, Tamiko Wierzbowski, Aleksandra Hoban, Daryl J |
author_sort | Zhanel, George G |
collection | PubMed |
description | Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP) are common conditions and constitute a substantial socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum of antibacterial activity. In vitro, telithromycin is active against common bacterial pathogens that cause upper and lower respiratory tract infections, including some isolates that are resistant to other antibiotic classes. In 2004, telithromycin was the first ketolide antibiotic approved for clinical use by the US Food and Drug Administration for the treatment of adult outpatients with ABS, AECB, and mild-to-moderate CAP. This review discusses the use of telithromycin in the treatment of these infections, providing an overview of its antibacterial activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability–safety, and concludes that telithromycin is an appropriate option for the treatment of community-acquired ABS, AECB, and mild-to-moderate CAP. |
format | Text |
id | pubmed-1661642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-16616422008-03-21 Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia Zhanel, George G Hisanaga, Tamiko Wierzbowski, Aleksandra Hoban, Daryl J Ther Clin Risk Manag Review Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP) are common conditions and constitute a substantial socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum of antibacterial activity. In vitro, telithromycin is active against common bacterial pathogens that cause upper and lower respiratory tract infections, including some isolates that are resistant to other antibiotic classes. In 2004, telithromycin was the first ketolide antibiotic approved for clinical use by the US Food and Drug Administration for the treatment of adult outpatients with ABS, AECB, and mild-to-moderate CAP. This review discusses the use of telithromycin in the treatment of these infections, providing an overview of its antibacterial activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability–safety, and concludes that telithromycin is an appropriate option for the treatment of community-acquired ABS, AECB, and mild-to-moderate CAP. Dove Medical Press 2006-03 2006-03 /pmc/articles/PMC1661642/ /pubmed/18360582 Text en © 2006 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Zhanel, George G Hisanaga, Tamiko Wierzbowski, Aleksandra Hoban, Daryl J Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title_full | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title_fullStr | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title_full_unstemmed | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title_short | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
title_sort | telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661642/ https://www.ncbi.nlm.nih.gov/pubmed/18360582 |
work_keys_str_mv | AT zhanelgeorgeg telithromycininthetreatmentofacutebacterialsinusitisacuteexacerbationsofchronicbronchitisandcommunityacquiredpneumonia AT hisanagatamiko telithromycininthetreatmentofacutebacterialsinusitisacuteexacerbationsofchronicbronchitisandcommunityacquiredpneumonia AT wierzbowskialeksandra telithromycininthetreatmentofacutebacterialsinusitisacuteexacerbationsofchronicbronchitisandcommunityacquiredpneumonia AT hobandarylj telithromycininthetreatmentofacutebacterialsinusitisacuteexacerbationsofchronicbronchitisandcommunityacquiredpneumonia |